Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
CLDX
CLDX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CLDX News
Celldex Reports Positive Phase 2b Data for Barzolvolimab in Angioedema Treatment
2d ago
NASDAQ.COM
Barzolvolimab Significantly Improves Angioedema in Chronic Spontaneous Urticaria Patients
3d ago
Newsfilter
Celldex's CDX-622 Shows Promising Phase 1 Results in Mast Cell Depletion
3d ago
Newsfilter
Celldex Reports Q1 Earnings Miss with Significant Revenue Decline
May 07 2026
seekingalpha
Major Wall Street Rating Updates on Monday
Apr 20 2026
CNBC
Celldex Closes $345 Million Public Offering of 11.9 Million Shares
Apr 06 2026
Newsfilter
Celldex Therapeutics Prices $300M Public Offering for Pipeline Expansion
Apr 02 2026
seekingalpha
Celldex Therapeutics Prices Public Offering at $29 per Share
Apr 02 2026
NASDAQ.COM
Celldex Announces Public Offering of Shares
Apr 02 2026
Newsfilter
Celldex Therapeutics Prices Public Offering of 10.3 Million Shares
Apr 02 2026
Yahoo Finance
Celldex Initiates Underwritten Public Offering to Support New Drug Launch
Apr 01 2026
seekingalpha
Celldex's Barzolvolimab Enhances Quality of Life in Chronic Urticaria Patients
Mar 27 2026
Newsfilter
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
Mar 21 2026
Yahoo Finance
Celldex's Barzolvolimab Shows Strong Efficacy in Skin Conditions
Mar 02 2026
NASDAQ.COM
Celldex Presents Positive Data on Barzolvolimab for ColdU and SD Treatment
Mar 01 2026
Newsfilter
Celldex Reports Positive Data on Barzolvolimab Efficacy
Feb 27 2026
Newsfilter
Show More News
